Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Short term Debt: 2010-2024

Historic Short term Debt for Northwest Biotherapeutics (NWBO) over the last 14 years, with Dec 2024 value amounting to $9.6 million.

  • Northwest Biotherapeutics' Short term Debt rose 5.13% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 5.13%. This contributed to the annual value of $9.6 million for FY2024, which is 4.24% up from last year.
  • According to the latest figures from FY2024, Northwest Biotherapeutics' Short term Debt is $9.6 million, which was up 4.24% from $9.2 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Short term Debt ranged from a high of $355.0 million in FY2020 and a low of $9.2 million during FY2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Short term Debt value was $9.6 million (recorded in 2024), while the average stood at $33.1 million.
  • In the last 5 years, Northwest Biotherapeutics' Short term Debt surged by 1,656.16% in 2020 and then slumped by 88.59% in 2023.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Short term Debt stood at $355.0 million in 2020, then tumbled by 69.92% to $106.8 million in 2021, then declined by 24.56% to $80.6 million in 2022, then slumped by 88.59% to $9.2 million in 2023, then grew by 4.24% to $9.6 million in 2024.